A Phase 1/2 interventional study of ACE Retino in Retinitis Pigmentosa (RP), Age Related Macular Degeneration and Diabetic Retinopathy, sponsored by Ace Cells Lab Limited. Recruiting at 2 sites in Egypt. Per ClinicalTrials.gov, last updated 2025-04-25.
Sponsored by Ace Cells Lab Limited · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Summary of the Study This clinical trial evaluates a novel peptide-based therapy for treating retinal dystrophies, age-related macular degeneration (AMD), and diabetic retinopathy (DR). The therapy consists of peptides derived from fetal tissues, mesenchymal stem cells (MSCs), and bioactive growth factors, administered sublingually for systemic absorption.
Study Objectives:
Primary Objectives: Assess safety and tolerability, and evaluate the therapy's effects on retinal function and structure.
Secondary Objectives: Explore improvements in visual acuity, retinal thickness, vascular health, and disease biomarkers.
Study Design:
Type: Open-label, single-arm interventional study. Duration: 12 months.
Participants: 150 adults, divided into three cohorts:
Retinal dystrophies. AMD (dry and wet forms). DR (moderate NPDR and PDR).
Intervention:
A sublingual solution containing peptides and growth factors, taken 4 times daily.
Outcome Measures:
Primary Outcomes: Safety (adverse events) and tolerability (treatment adherence).
Secondary Outcomes:
Functional: Visual acuity and field sensitivity improvements. Structural: Retinal thickness and vascular health. Biomarkers: Serum VEGF, oxidative stress, and inflammatory markers.
Study Procedures:
Monthly follow-ups for safety monitoring, vision tests, retinal imaging (OCT, FA), and blood biomarker analysis.
Comprehensive evaluations at baseline, 6 months, and 12 months. Significance: The study aims to provide an innovative, non-invasive treatment for debilitating retinal conditions, potentially improving vision and retinal health through systemic therapy.
Protocol for Evaluating a Novel Peptide-Based Therapy in Retinal Dystrophies, Age-Related Macular Degeneration, and Diabetic Retinopathy
Authors :
Mohamed Yasser Sayed Saif Prof of ophthalmology , Beni-Suef University Sherin Amer Family medicine consultant, Alaa Abdelkarim Endocrinology consultant , ACE Cells Lab Ahmed Tamer Sayed Saif Assistant Professor of ophthalmology, Fayoum University Passant Sayed Saif Assistant Professor of Ophthalmology, Misr University for Science and Technology
Background and Rationale Retinal diseases such as retinal dystrophies, age-related macular degeneration (AMD), and diabetic retinopathy (DR) are among the leading causes of blindness worldwide. These conditions result from different pathophysiological mechanisms but share common features like oxidative stress, chronic inflammation, and cellular degeneration.
The novel therapy under evaluation consists of low molecular weight peptides derived from fetal tissues and mesenchymal stem cells (MSCs). The formulation also incorporates bioactive growth factors and essential peptides to support retinal health and regeneration. Sublingual administration ensures systemic absorption and avoids invasive delivery methods.
<!-- -->
Primary Objectives
Secondary Objectives
Study Design • Type: Open-label, interventional, single-arm study.
Participants: 150 participants, stratified equally into three cohorts:
Participants 4.1 Inclusion Criteria
Intervention 5.1 Study Drug
Outcome Measures 6.1 Primary Outcomes • Safety:
<!-- -->
Functional Outcomes:
o BCVA changes measured using ETDRS charts.
Structural Outcomes:
o Retinal thickness and photoreceptor integrity evaluated by SD-OCT.
o Vascular leakage and neovascularization assessed using fluorescein angiography (FA) and OCT angiography (OCTA).
Biochemical and Biomarker Outcomes:
7.4 End-of-Study Visit (12 Months)
o Effect size and variability for BCVA improvement and retinal thickness changes are estimated from previous studies. A sample size of 150 ensures 80% power to detect a clinically meaningful difference at a 5% significance level.
Correlation analysis between biomarkers and functional outcomes.
Conducted per the Declaration of Helsinki and ICH-GCP guidelines. 2. IRB Approval: Secured before study commencement. 3. Informed Consent: Participants provided detailed study information and signed consent forms.
Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection. Lancet Glob Health. 2014;2
. doi:10.1016/S2214-109X(13)70145-1.
281 studies on the registry are indexed under Retinitis Pigmentosa; 74 are open to participants now.
This study's planned enrollment of 100 is above the median of 27 across 180 interventional studies indexed under Retinitis Pigmentosa.
Browse Retinitis Pigmentosa studies →Ace Cells Lab Limited is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adults aged 18-65 years with a confirmed genetic or clinical diagnosis of RP.
Exclusion Criteria:
Significant ocular comorbidities (e.g., advanced glaucoma, diabetic retinopathy).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Primary Objective: Evaluate the safety and tolerability of ACE Retino in individuals with RP.
Dietary Supplement: ACE Retino
Assess the efficacy of ACE Retino in improving retinal structure and function. Explore the potential for photoreceptor and retinal pigment epithelial (RPE) regeneration.
Dietary Supplement: ACE Retino
1 ml sublingually self administer / 4 times/day for 6 months
change in BVCA
change in BCVA (best-corrected visual acuity). The calculation is based on detecting a clinically meaningful improvement in BCVA using a paired design (before and after treatment within the same subjects).
Time frame: 3 months
change in OCT
change in OCT curves and numbers based on before and after results
Time frame: 3 months
Plan to share: Undecided
Started Nov 2024 (actual). Primary completion is estimated for Jun 2025, 7 months after the start.
Of 29 phase 1/2 interventional studies under Retinitis Pigmentosa, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 92. This study's planned 7 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ace Cells Lab Limited